Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
WVE Wave Life Sciences Ltd
- Stocks
- Healthcare
- NASDAQ: WVE
Price (delayed)
$6.575
Market cap
$1.01B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.7
Enterprise value
$732.5M
Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using
Highlights
The quick ratio has soared by 130% YoY and by 51% QoQ
The equity has grown by 48% from the previous quarter
Wave Life Sciences's revenue has surged by 102% QoQ but it has decreased by 4.4% YoY
WVE's gross profit has soared by 102% since the previous quarter but it is down by 4.4% year-on-year
Key stats
What are the main financial stats of WVE
Market
Valuations
Earnings
Shares outstanding
153.49M
Market cap
$1.01B
Enterprise value
$732.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.79
Price to sales (P/S)
8.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.76
Revenue
$108.3M
Gross profit
$108.3M
Operating income
-$110.4M
Net income
-$97.01M
EBIT
-$97.01M
EBITDA
-$88.35M
Free cash flow
-$151.96M
Per share
Balance sheet
Liquidity
EPS
-$0.7
EPS diluted
-$0.7
Free cash flow per share
-$1.1
Book value per share
$1.37
Revenue per share
$0.78
TBVPS
$2.55
Total assets
$352.21M
Total liabilities
$134.82M
Debt
$25.4M
Equity
$209.52M
Working capital
$209.44M
Debt to equity
0.12
Current ratio
2.89
Quick ratio
2.74
Net debt/EBITDA
3.13
Margins
Efficiency
Dividend
EBITDA margin
-81.6%
Gross margin
100%
Net margin
-89.6%
Operating margin
-101.9%
Return on assets
-33.6%
Return on equity
-104%
Return on invested capital
N/A
Return on capital employed
-40.2%
Return on sales
-89.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WVE stock price
How has the Wave Life Sciences stock price performed over time
Intraday
0.54%
1 week
-18.83%
1 month
7.08%
1 year
14.15%
YTD
-46.85%
QTD
-18.63%
Financial performance
How have Wave Life Sciences's revenue and profit performed over time
Revenue
$108.3M
Gross profit
$108.3M
Operating income
-$110.4M
Net income
-$97.01M
Gross margin
100%
Net margin
-89.6%
Wave Life Sciences's revenue has surged by 102% QoQ but it has decreased by 4.4% YoY
WVE's gross profit has soared by 102% since the previous quarter but it is down by 4.4% year-on-year
Wave Life Sciences's net margin has shrunk by 76% YoY but it has surged by 66% QoQ
The operating margin has plunged by 70% YoY but it has soared by 64% from the previous quarter
Price vs fundamentals
How does WVE's price correlate with its fundamentals
Growth
What is Wave Life Sciences's growth rate over time
Valuation
What is Wave Life Sciences stock price valuation
P/E
N/A
P/B
4.79
P/S
8.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.76
Wave Life Sciences's EPS has increased by 37% from the previous quarter but it has decreased by 30% YoY
The equity has grown by 48% from the previous quarter
Wave Life Sciences's revenue has surged by 102% QoQ but it has decreased by 4.4% YoY
The P/S is 65% below the 5-year quarterly average of 24.2 and 32% below the last 4 quarters average of 12.2
Efficiency
How efficient is Wave Life Sciences business performance
Wave Life Sciences's ROS has plunged by 74% YoY but it has soared by 66% from the previous quarter
Wave Life Sciences's return on equity has surged by 63% QoQ
WVE's return on assets is down by 42% year-on-year but it is up by 36% since the previous quarter
Dividends
What is WVE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WVE.
Financial health
How did Wave Life Sciences financials performed over time
The total assets is 161% greater than the total liabilities
The quick ratio has soared by 130% YoY and by 51% QoQ
WVE's current ratio has soared by 129% year-on-year and by 52% since the previous quarter
Wave Life Sciences's debt is 88% lower than its equity
Wave Life Sciences's debt to equity has plunged by 85% YoY and by 37% from the previous quarter
The equity has grown by 48% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.